Save time and get answers to complex questions with AI chat
Quartette side effects?Are there specific stretches to avoid while on lipitor?What is dabrafenib mesylate msn patent issue?When is tenofovir alafenamide patent expiring?How does iron rich food intake impact lipitor's efficacy?
See the DrugPatentWatch profile for Repatha
Repatha (evolocumab) was launched in the U.S. in 2015, after the FDA approved it for certain patients with hyperlipidemia and cardiovascular risk conditions.
The U.S. FDA approval that enabled the product’s commercial launch occurred on August 27, 2015 (the date most launch timelines reference).
Launch timing varied by country, because availability depends on each regulator’s approval and local pricing/coverage decisions. In most markets, rollouts started soon after the initial approvals in 2015.
“Launch” can refer to different milestones, such as: - first regulatory approval (e.g., FDA approval in 2015), - first shipment/commercial availability in a specific country, - label expansion approvals later on. Those events can create different dates in news articles, formularies, and analyst reports.
Other Questions About Repatha :